| TRT | Testosterone Replacement Therapy |
| PADAM | Partial Androgen Deficiency of the Aging Male |
| LOH | Late-Onset Hypogonadism |
| LH | Luteinizing hormone |
| COX2 | cyclooxygenase-2 |
| StAR | steroidogenic acute regulatory protein |
| BMI | Body Mass Index |
| AR | androgen receptor |
| PPARγ | Peroxisome Proliferator-Activated Receptor-gamma |
| CEBPα | CAT/enhancer-binding protein alpha |
| IM | intramuscular |
| RCT | Randomized Clinical Trial |
| DHEA | Dehydroepiandrosterone |
| DHEAS | Dehydroepiandrosterone sulfate |
| BMD | bone mineral density |
| IIEF | International Index of Erectile Function |
| EFD | Erectile Function Domain |
| PDE-5i | phosphodiesterase type 5 inhibitors |
| SAID | Sexual Arousal, Interest and Drive Scale |
| HED | Hypogonadism Energy Diary |
| T2DM | Type 2 diabetes mellitus |
| HbA1c | glycated hemoglobin |
| HOMA-IR | homeostatic model assessment of insulin resistance |
| IL-18 | interleukin 18 |
| ADT | Androgen deprivation therapy |
| CV | cardiovascular |
| FDA | Food and drug administration |
| QoL | Quality of life |
| AMS | Aging Males’ Symptom |
| ED | Erectile dysfunction |